MedMira Receives FDA Approval for Reveal G3 Rapid HIV Test - Fastest Rapid HIV Test in the US, Delivering Results in Less Than 3 Minutes

Oct 19, 2006, 01:00 ET from MEDMIRA INC.

    HALIFAX, Oct. 19 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira")
 (TSX Venture: MIR, NASDAQ:   MMIRF) a global market leader in premium rapid
 diagnostic solutions, announced today that it has received United States
 Food and Drug Administration (FDA) approval for its Reveal(R) G3 Rapid
 HIV-1 Antibody Test (Reveal G3). Reveal G3, which delivers test results in
 less than three minutes, is the third generation in the Reveal line of
 rapid HIV tests. Previous versions of the product were approved by the FDA
 in 2003 and 2004.
     Reveal G3 includes the addition of MedMira's InstantGold(TM) Cap which
 replaces the colorimetric detection agent used to visualize results on the
 test cartridge. This advancement eliminates the need for reconstitution and
 refrigeration of the colorimetric detection agent, improving the product's
 overall ease-of-use. MedMira now offers Reveal G3 in a box of 30, a new
 size format designed to maximize efficiency of all components included in
 the test package.
     "We are very pleased to receive approval on the third generation of
 Reveal, which brings to market key advancements that will drive further
 adoption of rapid HIV testing in point of care settings," said Hermes Chan,
 President & CEO, MedMira Inc. "HIV continues to be one of the greatest
 health challenges in the US and the healthcare system is taking steps to
 address the control and prevention of this epidemic."
     On September 21st, the US Centers for Disease Control and Prevention's
 (CDC) announced new recommendations on routine HIV testing for everyone 13
 to 64 years of age. As this latest initiative takes hold in the healthcare
 system, MedMira anticipates continued growth in the rapid testing sector.
 The CDC estimates that there are over 250,000 HIV-positive people in the US
 who are unaware of their status. The recent CDC recommendations also
 include enhanced screening of pregnant women to decrease the rate of
 mother-to-child transmission. Key applications for MedMira's Reveal G3 test
 include Labor & Delivery, Occupational Exposures, and Emergency
 Departments. MedMira's Reveal tests have ranked as a leading choice in
 rapid HIV tests for US hospitals and laboratories over the past several
     About MedMira
     MedMira is a leading developer and manufacturer of flow-through rapid
 diagnostics. The company's tests provide hospitals, labs, clinics and
 individuals around the world with reliable, rapid diagnosis for diseases
 such as HIV and hepatitis C in just three minutes. The company's tests are
 sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands
 in global markets. MedMira's rapid HIV test is the only one in the world to
 achieve regulatory approvals in Canada, the United States, China and the
 European Union.
     The company's corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office in
 China. For more information visit MedMira's website at
     This news release contains forward-looking statements, which involve
 risk and uncertainties and reflect the company's current expectation
 regarding future events. Actual events could materially differ from those
 projected herein and depend on a number of factors including, but not
 limited to, changing market conditions, successful and timely completion of
 clinical studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.